EpiBiologics vs Saama Analytics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $107M Series B (Jan 2026) co-led by J&J Ventures and Google Ventures. EpiTAC targets membrane and secreted proteins — expanding degradation beyond intracellular-only. EPI-326 entering Phase 1 H1 2026.
About
EpiBiologics develops EpiTAC — a targeted protein degradation platform designed to eliminate membrane and secreted proteins that existing degrader technologies cannot reach. The company raised $107 million in Series B financing in January 2026, co-led by Johnson & Johnson Ventures and Google Ventures, a rare investor pairing that brings both pharma development expertise and computational biology capabilities. The lead program, EPI-326 (an EGFR degrader for non-small cell lung cancer), is entering Phase 1 clinical trials in the first half of 2026.
Saama Analytics is the #1 AI clinical analytics platform for life sciences; received up to $430M Carlyle-led investment in May 2025; serves 50+ biotech companies across 1,500+ studies including top-20 pharma.
About
Saama Analytics is the leading AI-driven clinical analytics and data management platform for the life sciences industry, positioning itself as the "#1 in AI Clinical Analytics" based on customer adoption across major pharmaceutical and biotechnology companies. Founded and headquartered in the United States, Saama's Life Science Analytics Cloud (LSAC) platform accelerates clinical trial execution by automating data processing, quality checking, safety signal detection, and regulatory submission preparation — tasks that traditionally require significant manual effort from biostatisticians, data managers, and clinical programmers.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.